Compass Therapeutics Inc

NASDAQ:CMPX   3:59:53 PM EDT
2.74
+0.06 (+2.24%)
Earnings Announcements

Compass Therapeutics Reports Second Quarter 2022 Financial Results And Provides Corporate Update

Published: 08/01/2022 13:47 GMT
Compass Therapeutics Inc (CMPX) - Compass Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update.
$132.0 Million in Cash and Marketable Securities As of June 30, 2022, With Anticipated Cash Runway Into 2h 2024.
A Combination Study of Ctx-471 and Pd-1 Blocker is on Track to Initiate in Q4 2022.
Net Loss for Q2 Ended June 30, 2022, Was $8.5 Million Or $0.08 per Common Share.
Q2 Earnings per Share View $-0.08 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.10

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.10

More details on our Analysts Page.